ACADIA Pharmaceuticals Wins Favorable Patent Court Ruling

ACADIA Pharmaceuticals ( (ACAD) ) has provided an announcement.

On May 15, 2025, ACADIA Pharmaceuticals entered into a 12-year lease agreement for new executive office space at 210 Carnegie Center in Princeton, New Jersey, with plans for commercial, research, and development activities. The company will pay an initial annual rent of $1,899,756, with incremental increases, and is responsible for operating expenses and property taxes. Additionally, ACADIA announced a favorable court ruling on May 16, 2025, regarding its formulation patent for NUPLAZID®, securing its position against competitors Aurobindo Pharma and MSN Laboratories.

The most recent analyst rating on (ACAD) stock is a Hold with a $20.00 price target. To see the full list of analyst forecasts on ACADIA Pharmaceuticals stock, see the ACAD Stock Forecast page.

Spark’s Take on ACAD Stock

According to Spark, TipRanks’ AI Analyst, ACAD is a Outperform.

ACADIA Pharmaceuticals demonstrates strong financial performance, with notable strengths in revenue growth and profitability. The stock’s technical indicators suggest a strong upward trend, although the high RSI warns of potential overbought conditions. The company’s valuation is reasonable, supporting its growth potential. The recent earnings call was positive, emphasizing strategic growth and international expansion, despite some operational challenges.

To see Spark’s full report on ACAD stock, click here.

More about ACADIA Pharmaceuticals

ACADIA Pharmaceuticals operates in the biopharmaceutical industry, focusing on the development and commercialization of innovative medicines for central nervous system disorders. Its primary product is NUPLAZID® (pimavanserin), a drug for the treatment of Parkinson’s Disease Psychosis.

Average Trading Volume: 2,091,542

Technical Sentiment Signal: Strong Buy

Current Market Cap: $3.68B

See more data about ACAD stock on TipRanks’ Stock Analysis page.